Publicación:
Genomic epidemiology of SARS-CoV-2 in Bolivia, 2020–2024

dc.contributor.authorPérez-Cascales, Esdenka
dc.contributor.authorCaballero, Francesca
dc.contributor.authorMartínez-Ventura, Anne
dc.contributor.authorAyzanoa, Brenda
dc.contributor.authorPrado-Zapata, Mauricio
dc.contributor.authorBaldiviezo-Soliz, Eliana
dc.contributor.authorCarballo-Jiménez, Paula
dc.contributor.authorTinajeros-Guzmán, Freddy
dc.contributor.authorCuicapuza, Diego
dc.contributor.authorTsukayama, Pablo
dc.date.accessioned2026-05-01T06:26:33Z
dc.date.issued2025
dc.description.abstractThe COVID-19 pandemic has severely impacted Bolivia due to its high social vulnerability and limited healthcare resources. In response to the limited local capacity for genomic surveillance during the pandemic, we characterized the genetic diversity and geographic distribution of SARS-CoV-2 variants across Bolivia from 2020 to 2024. A total of 714 SARS-CoV-2 genomic sequences were analyzed, including 313 newly sequenced samples and 401 retrieved from GISAID, allowing us to track viral evolution across six epidemic waves. The first wave, dominated by the Wuhan B.1 lineage, resulted in 8,943 deaths, while the fourth wave, characterized by the Omicron BA variant, had the highest infection rates, with approximately 80,000 confirmed cases. While mortality decreased in later waves, case numbers remained high due to the emergence of variants with increased transmissibility and immune escape. Our findings underscore the dynamic evolution of SARS-CoV-2 in Bolivia and highlight the critical need for sustained genomic surveillance to monitor emerging variants and inform public health strategies, particularly in resource-limited settings. Strengthening genomic surveillance, especially in cross-border regions, will mitigate future epidemic waves and improve pandemic preparedness. Copyright © 2025 Pérez-Cascales et al.en_US
dc.description.sponsorshipFunding text 1: This study was funded by Programa Nacional de Investigaci\u00F3n y Estudios Avanzados (PROCIENCIA-CONCYTEC) grant PE501086419-2024. A.M.V. and D.C. are supported by a D43 TW007393 training grant awarded to UPCH by the Fogarty International Center of the U.S. National Institutes of Health. The study protocol was approved by the Institutional Review Board at Universidad Peruana Cayetano Heredia (SIDISI 205559).; Funding text 2: This study was funded by Programa Nacional de Investigaci\u00F3n Cient\u00EDfica y Estudios Avanzados (PROCIENCIA-CONCYTEC) grant PE501086419-2024. A.M.V. and D.C. are supported by a D43 TW007393 training grant awarded to UPCH by the Fogarty International Center of the U.S. National Institutes of Health. The study protocol was approved by the Institutional Review Board at Universidad Peruana Cayetano Heredia (SIDISI 205559).es_PE
dc.identifier.doihttps://doi.org/10.1128/spectrum.01280-25
dc.identifier.scopus2-s2.0-105014988787
dc.identifier.urihttps://hdl.handle.net/20.500.12866/19471
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.relation.ispartofurn:issn:2165-0497
dc.relation.ispartofseriesMicrobiology Spectrum
dc.relation.issn2165-0497
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectmolecular epidemiologyen_US
dc.subjectphylogeneticsen_US
dc.subjectSARS-CoV-2en_US
dc.titleGenomic epidemiology of SARS-CoV-2 in Bolivia, 2020–2024en_US
dc.typehttps://purl.org/coar/resource_type/c_2df8fbb1
dc.type.localArtículo de revista
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication

Archivos